MENRIUM 5-2
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MENRIUM 5-2 (MENRIUM 5-2).
Combination of chlordiazepoxide (benzodiazepine) potentiating GABA-A receptor activity, and clidinium (antimuscarinic) blocking muscarinic acetylcholine receptors.
| Metabolism | Chlordiazepoxide: Hepatic via CYP3A4; active metabolite desmethylchlordiazepoxide. Clidinium: Primarily hepatic; exact enzymes not well characterized. |
| Excretion | Chlordiazepoxide: 90-96% renal as metabolites, <5% unchanged; Clidinium: 70-80% fecal, 10-20% renal as metabolites |
| Half-life | Chlordiazepoxide: 5-30 hours (increases with age, hepatic impairment); Clidinium: 8-12 hours |
| Protein binding | Chlordiazepoxide: 95-98% (albumin); Clidinium: 50% (albumin) |
| Volume of Distribution | Chlordiazepoxide: 0.3-0.5 L/kg; Clidinium: 1-2 L/kg (extensive tissue distribution) |
| Bioavailability | Oral: 100% (chlordiazepoxide); 10-20% (clidinium, due to first-pass metabolism) |
| Onset of Action | Oral chlordiazepoxide: 30-60 minutes; oral clidinium: 1-2 hours |
| Duration of Action | Chlordiazepoxide: 6-24 hours (active metabolites extend effect); Clidinium: 3-6 hours (anticholinergic effects) |
1 tablet orally every 6-8 hours as needed for anxiety, up to 4 tablets per day. Each tablet contains chlordiazepoxide 5 mg and clidinium bromide 2.5 mg.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-60 mL/min: no adjustment unless accumulation occurs; CrCl <30 mL/min: avoid due to increased risk of sedation and anticholinergic effects. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B/C: avoid use or reduce dose by 50-75% due to reduced clearance of chlordiazepoxide. |
| Pediatric use | Not recommended for children <18 years old due to lack of safety and efficacy data. |
| Geriatric use | Initial dose: 1 tablet orally once or twice daily; increase slowly to avoid excessive sedation, confusion, and anticholinergic adverse effects; maximum 4 tablets per day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MENRIUM 5-2 (MENRIUM 5-2).
| Breastfeeding | Contraindicated in breastfeeding. No M/P ratio reported. Excreted into breast milk; may cause sedation, feeding difficulties, and hypotonia in the infant. |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: increased risk of congenital malformations, particularly cleft palate and cardiovascular defects; second and third trimesters: risk of fetal CNS depression, neonatal withdrawal syndrome, and floppy infant syndrome. |
| Fetal Monitoring |
■ FDA Black Box Warning
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
| Serious Effects |
["Hypersensitivity to chlordiazepoxide or clidinium","Narrow-angle glaucoma","Obstructive uropathy","Myasthenia gravis","Severe hepatic impairment","Concomitant use with opioids (except for alternative treatments)"]
| Precautions | ["Risk of addiction, abuse, and misuse","Dependence and withdrawal reactions","Concomitant use with opioids","CNS depressant effects and impaired cognition","Paradoxical reactions","Anticholinergic effects (e.g., constipation, urinary retention)","Glaucoma risk","Use in elderly or debilitated patients"] |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and respiratory status; fetal heart rate monitoring during third trimester; neonatal assessment for withdrawal symptoms and floppy infant syndrome. |
| Fertility Effects | May cause menstrual irregularities, anovulation, and galactorrhea due to hyperprolactinemia; reversible upon discontinuation. |